Exclusive Summary

• - Global PCI volumes are ~3–4 million/year, with eptifibatide retaining steady demand in high-thrombus and bailout settings.
• - US and EU27 registrations enable dossier reliance and faster access in additional markets with strong compliance credentials.
• - Two strengths (20mg/10ml and 75mg/100ml) cover bolus and maintenance infusion, reducing compounding steps and medication errors for hospital tenders.
• - Multiple guidelines position it as a bailout/high-risk option in PCI; short half-life and reversible inhibition support perioperative management.
• - Versus the originator, generics typically deliver 40–70% price reductions, supporting penetration via centralized procurement and distribution.